Cargando…
Ethical and scientific issues in studying the safety of approved drugs /
"An estimated 48 percent of the population takes at least one prescription drug in a given month. Drugs provide great benefits to society by saving or improving lives. Many drugs are also associated with side effects or adverse events, some serious and some discovered only after the drug is on...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Washington, D.C. :
National Academies Press,
©2012.
|
| Colección: | Online access: National Academy of Sciences National Academies Press.
Online access: NCBI NCBI Bookshelf. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ma 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn811594850 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 120529s2012 dcua ob 001 0 eng d | ||
| 010 | |z 2012021854 | ||
| 040 | |a CEF |b eng |e pn |c CEF |d CEF |d INT |d VT2 |d OCLCQ |d OCLCO |d AU@ |d ZCU |d WYU |d OCLCQ |d OCLCO |d UWO |d LVT |d YOU |d OCLCQ |d STF |d AGLDB |d DKC |d OCLCO |d OCLCQ |d M8D |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ |d OCLCA |d UKAHL |d OCLCQ |d OCLCA |d UKCRE |d VLY |d AJS |d OCLCO |d DST |d VHC |d OCLCO |d OCLCQ |d OCLCO |d OCLCL |d EZC |d OCLCF |d INARC | ||
| 019 | |a 807995581 |a 813396136 |a 817819229 |a 961588569 |a 962602470 |a 988443543 |a 990687182 |a 992062784 |a 994403202 |a 1028757443 |a 1034950830 |a 1038657339 |a 1045517324 |a 1047272810 |a 1071917238 |a 1153543516 |a 1162391150 |a 1204377150 |a 1229716924 |a 1290053333 |a 1300475295 |a 1303345489 |a 1303502078 |a 1310604563 | ||
| 020 | |a 9780309218146 |q (electronic bk.) | ||
| 020 | |a 0309218144 |q (electronic bk.) | ||
| 020 | |z 9780309218139 | ||
| 020 | |z 0309218136 | ||
| 020 | |z 661394890X | ||
| 020 | |z 9786613948908 | ||
| 020 | |z 1283636441 | ||
| 020 | |z 9781283636445 | ||
| 020 | |a 0309218160 | ||
| 020 | |a 9780309218160 | ||
| 029 | 1 | |a AU@ |b 000051593836 | |
| 029 | 1 | |a DEBBG |b BV044052118 | |
| 029 | 1 | |a NZ1 |b 15196462 | |
| 035 | |a (OCoLC)811594850 |z (OCoLC)807995581 |z (OCoLC)813396136 |z (OCoLC)817819229 |z (OCoLC)961588569 |z (OCoLC)962602470 |z (OCoLC)988443543 |z (OCoLC)990687182 |z (OCoLC)992062784 |z (OCoLC)994403202 |z (OCoLC)1028757443 |z (OCoLC)1034950830 |z (OCoLC)1038657339 |z (OCoLC)1045517324 |z (OCoLC)1047272810 |z (OCoLC)1071917238 |z (OCoLC)1153543516 |z (OCoLC)1162391150 |z (OCoLC)1204377150 |z (OCoLC)1229716924 |z (OCoLC)1290053333 |z (OCoLC)1300475295 |z (OCoLC)1303345489 |z (OCoLC)1303502078 |z (OCoLC)1310604563 | ||
| 037 | |a 3564274 |b Proquest Ebook Central | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a RM301.27 |b .E84 2012 | |
| 060 | 4 | |a QV 771 | |
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a BUS |x 008000 |2 bisacsh | |
| 082 | 0 | 4 | |a 174.2/951 |2 23 |
| 049 | |a UAMI | ||
| 245 | 0 | 0 | |a Ethical and scientific issues in studying the safety of approved drugs / |c Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies. |
| 260 | |a Washington, D.C. : |b National Academies Press, |c ©2012. | ||
| 300 | |a 1 online resource (xvi, 275 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file |2 rda | ||
| 500 | |a Title screen viewed on Sept. 24, 2012. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Introduction -- Incorporating benefit and risk assessment and benefit-risk management into food and drug administration decision-making -- Evidence and decision-making -- Selection and oversight of required postmarketing studies -- Synthesis -- Appendixes. | |
| 520 | |a "An estimated 48 percent of the population takes at least one prescription drug in a given month. Drugs provide great benefits to society by saving or improving lives. Many drugs are also associated with side effects or adverse events, some serious and some discovered only after the drug is on the market. The discovery of new adverse events in the postmarketing setting is part of the normal natural history of approved drugs, and timely identification and warning about drug risks are central to the mission of the Food and Drug Administration (FDA). Not all risks associated with a drug are known at the time of approval, because safety data are collected from studies that involve a relatively small number of human subjects during a relatively short period. Written in response to a request by the FDA, Ethical and Scientific Issues in Studying the Safety of Approved Drugs discusses ethical and informed consent issues in conducting studies in the postmarketing setting. It evaluates the strengths and weaknesses of various approaches to generate evidence about safety questions, and makes recommendations for appropriate followup studies and randomized clinical trials. The book provides guidance to the FDA on how it should factor in different kinds of evidence in its regulatory decisions. Ethical and Scientific Issues in Studying the Safety of Approved Drugs will be of interest to the pharmaceutical industry, patient advocates, researchers, and consumer groups"--Publisher's description. | ||
| 546 | |a English. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Drugs |x Testing |x Moral and ethical aspects |z United States. | |
| 650 | 0 | |a Drug approval |z United States. | |
| 650 | 0 | |a Clinical trials |x Moral and ethical aspects |z United States. | |
| 650 | 1 | 2 | |a Drug Evaluation |x ethics |
| 650 | 2 | 2 | |a Clinical Trials as Topic |x ethics |
| 650 | 2 | 2 | |a Drug Approval |
| 650 | 2 | 2 | |a Product Surveillance, Postmarketing |x methods |
| 651 | 2 | |a United States | |
| 650 | 6 | |a Médicaments |x Essais cliniques |x Aspect moral |z États-Unis. | |
| 650 | 6 | |a Études cliniques |x Aspect moral |z États-Unis. | |
| 650 | 6 | |a Médicaments |x Autorisation de mise sur le marché |z États-Unis. | |
| 650 | 7 | |a BUSINESS & ECONOMICS |x Business Ethics. |2 bisacsh | |
| 650 | 7 | |a Clinical trials |x Moral and ethical aspects |2 fast | |
| 650 | 7 | |a Drug approval |2 fast | |
| 650 | 7 | |a Drugs |x Testing |x Moral and ethical aspects |2 fast | |
| 651 | 7 | |a United States |2 fast |1 https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq | |
| 655 | 7 | |a dissertations. |2 aat | |
| 655 | 7 | |a Academic theses |2 fast | |
| 655 | 7 | |a Academic theses. |2 lcgft | |
| 655 | 7 | |a Thèses et écrits académiques. |2 rvmgf | |
| 710 | 2 | |a Institute of Medicine (U.S.). |b Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs. | |
| 758 | |i has work: |a Ethical and Scientific Issues in Studying the Safety of Approved Drugs (Text) |1 https://id.oclc.org/worldcat/entity/E39PCYC8DG6j4Y7dmMb7rFCWWC |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t Ethical and scientific issues in studying the safety of approved drugs. |d Washington, D.C. : National Academies Press, ©2012 |z 9780309218139 |w (DLC) 2012944110 |w (OCoLC)822995300 |
| 830 | 0 | |a Online access: National Academy of Sciences National Academies Press. | |
| 830 | 0 | |a Online access: NCBI NCBI Bookshelf. | |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=3564274 |z Texto completo |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36559653 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36617456 | ||
| 938 | |a Coutts Information Services |b COUT |n 23606266 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL3564274 | ||
| 938 | |a ebrary |b EBRY |n ebr10606354 | ||
| 938 | |a EBSCOhost |b EBSC |n 991052 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n 394890 | ||
| 938 | |a YBP Library Services |b YANK |n 9753172 | ||
| 938 | |a Internet Archive |b INAR |n ethicalscientifi0000unse | ||
| 994 | |a 92 |b IZTAP | ||